|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1993-11-10
|
|
pubmed:abstractText |
A Phase II clinical trial was conducted to evaluate the efficacy of intravenous fluorouracil (5-FU) and subcutaneous recombinant interferon-alpha-2b (rIFN-alpha-2b) in the treatment of hepatocellular carcinoma (HCC) and to define factors that might be predictive of a response to treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2574-82
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7691392-Adolescent,
pubmed-meshheading:7691392-Adult,
pubmed-meshheading:7691392-Aged,
pubmed-meshheading:7691392-Biological Markers,
pubmed-meshheading:7691392-Carcinoma, Hepatocellular,
pubmed-meshheading:7691392-Chemotherapy, Adjuvant,
pubmed-meshheading:7691392-Female,
pubmed-meshheading:7691392-Fluorouracil,
pubmed-meshheading:7691392-Humans,
pubmed-meshheading:7691392-Interferon-alpha,
pubmed-meshheading:7691392-Male,
pubmed-meshheading:7691392-Middle Aged,
pubmed-meshheading:7691392-Recombinant Proteins,
pubmed-meshheading:7691392-Remission Induction,
pubmed-meshheading:7691392-Survival Analysis,
pubmed-meshheading:7691392-alpha-Fetoproteins
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.
|
|
pubmed:affiliation |
Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas M.D. Anderson Cancer Center, Houston 77030.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
